Tim Brandenburg Vera Tiedje Philipp Muchalla Sarah Theurer Frank Weber Kurt Werner Schmid Henning Dralle Dagmar Führer
10.3389/fendo.2021.718418
Front Endocrinol (Lausanne)
2021 Sep 29;12:718418.
calcitonin doubling time medullary thyroid carcinoma multiple endocrine neoplasia type 2a therapy discontinuation tyrosine kinase inhibitor therapy
CC BY
https://pubmed.ncbi.nlm.nih.gov/34659114/
Carcinoma, Neuroendocrine / drug therapy Drug-Related Side Effects and Adverse Reactions / pathology Piperidines / adverse effects Protein Kinase Inhibitors / adverse effects Quinazolines / adverse effects Thyroid Neoplasms / drug therapy Withholding Treatment / statistics & numerical data
Carcinoma, Neuroendocrine / drug therapy Drug-Related Side Effects and Adverse Reactions / pathology Piperidines / adverse effects Protein Kinase Inhibitors / adverse effects Quinazolines / adverse effects Thyroid Neoplasms / drug therapy Withholding Treatment / statistics & numerical data Adult Carcinoma, Neuroendocrine / pathology Drug-Related Side Effects and Adverse Reactions / etiology Female Follow-Up Studies Humans Male Middle Aged Prognosis Retrospective Studies Thyroid Neoplasms / pathology Young Adult Piperidines Protein Kinase Inhibitors Quinazolines vandetanib Thyroid cancer, medullary
PMC8511790
34659114
Continued Discontinuation of TKI Treatment in Medullary Thyroid Carcinoma - Lessons From Individual Cases With Long-Term Follow-Up
2021